NVO - Novo Nordisk A/S Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

NVO

NOVO NORDISK A/S

NYSE

$45.61

▼ DOWN 1.41% (-0.65)

KEY STATISTICS

Market Cap$202.54 B

52w High$64.16

52w Low$35.12

Dividend Yield2.53%

FrequencySemi-Annual

P/E11.35

Volume8.49M

Shares Out.4.44B

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Maziar Mike Doustdar

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 30, 1981

METHOD OF GOING PUBLIC

Dual Listing

FULL TIME EMPLOYEES

68,794

PRICE TARGET

Target High$47.00

Target Low$47.00

Target Median$47.00

Target Consensus$47.00

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$11.22B

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2023-09-20	Forward	2:1
2014-01-09	Forward	5:1
2007-12-17	Forward	2:1
2001-04-11	Forward	5:2
1994-04-18	Forward	4:1

PRICE

$45.61 ▼ DOWN 1.41% (−$0.65)

OVERLAYS

About Novo Nordisk A/S

https://www.novonordisk.com ↗

Novo Nordisk A/S develops and distributes pharmaceutical products for diabetes, obesity, rare diseases, and related therapies worldwide, offering innovative solutions like smart insulin pens and collaborating with organizations like UNICEF.

INDUSTRY

Drug Manufacturers - General

A PRODUCT NOVO NORDISK A/S IS KNOWN FOR

Wegovy (semaglutide) tablets

Launching in early 2026, this once-daily oral GLP-1 receptor agonist offers adults with obesity or overweight a needle-free, convenient option for weight management, marking the first U.S. approval of its kind.